OncBioMune Pharmaceuticals, Inc. (OBMP) is “One to Watch”
Given the latest official data on prostate cancer prevalence compiled by the CDC and the GLOBOCAN project, over 1.1 million cases of what is the fourth most common cancer in both sexes combined and the second most common cancer in men, were reported back in 2012 alone. Prostate cancer accounts for roughly 15 percent of … Continue reading “OncBioMune Pharmaceuticals, Inc. (OBMP) is “One to Watch””